Form 4: Rashmi Kumar Receives Myriad Genetics Equity Grant

Director Rashmi Kumar was granted 59,701 restricted stock units in Myriad Genetics, Inc. as part of the 2026 equity incentive plan.

Summary

• Director Rashmi Kumar acquired 59,701 restricted stock units (RSUs) on June 4, 2026.
• The grant was issued under the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of common stock.
• The total beneficial ownership for the director following this transaction is 186,889 shares.
• The RSUs vest on the earlier of the first anniversary of the grant or the date of the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard equity incentive grant consistent with corporate governance practices.

Negatives

• None identified.

Risks

• Vesting is subject to the terms of the 2026 Equity Incentive Plan.
• Value of the equity is subject to market fluctuations in Myriad Genetics common stock.

Future Outlook

The RSUs will vest on the earlier of the first anniversary of the grant (June 4, 2027) or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The grant structure follows standard industry practices for director compensation in mid-cap biotech firms.
• Vesting schedules align with typical annual meeting cycles observed in peer companies like Exact Sciences or Natera.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal impact; reflects standard director compensation practices.

Next Steps

• Vesting of the 59,701 RSUs on the earlier of June 4, 2027, or the next annual meeting.

Key Dates

Keywords

Myriad Genetics, MYGN, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation